Immunologic Responses to a Live Attenuated Oral Cholera Vaccine

Next Previous
Trial Profile

Immunologic Responses to a Live Attenuated Oral Cholera Vaccine

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Feb 2018

At a glance

  • Drugs PXVX 0200 (Primary)
  • Indications Cholera
  • Focus Pharmacodynamics

    • Most Recent Events

    • 30 Oct 2017 Planned End Date changed from 31 Dec 2018 to 30 Nov 2018.
    • 30 Oct 2017 Status changed from recruiting to active, no longer recruiting.
    • 18 Aug 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top